This is a promotional website developed by AstraZeneca and intended for UK Healthcare Professionals only. Other UK residents please visit astrazeneca.co.uk.
- For you
- For your patients
Resources for you
Dosing, monitoring and management
Managing cutaneous adverse drug reactions guide
Discover practical guidance on
managing TRUQAP-associated cutaneous
adverse drug reactions in patients with
HR+/HER2-negative aBC, along with key
findings from the CAPItello-291 trial,
information on assessing AE severity
and dermatologist-recommended
management strategies.
Genomic testing
Biomarker testing guide
Read a comprehensive overview of
biomarker testing in HR+/HER2-negative
aBC, including the role of NGS from
diagnosis to treatment recommendations.
You can also find advice on sample types,
when to test and how to interpret and
discuss results with your patients.
Genomic testing factsheet
Learn more about detecting
PIK3CA/AKT1/PTEN alterations in HR+/
HER2-negative aBC, with best practice
guidance for when, how and where to
perform genomic testing.
Genomic testing flashcard
Refresh your understanding of why, when
and how to test patients for PIK3CA/AKT1/
PTEN alterations with this summary sheet.
GB-68388 | April 2026
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to AstraZeneca by visiting https://contactazmedical.astrazeneca.com/ or by calling 0800 783 0033.
This website was created for UK HCPs and has been designed to provide information to educate, empower and enable them in the great work they are doing for patients across a range of therapy areas. This website is intended for doctors, nurses, and pharmacists in the UK. Other UK residents please visit astrazeneca.co.uk.